Half a year later, Teva's 'pivot to growth' strategy appears to be bearing fruit

Six months on, Teva’s new “pivot to growth” strategy appears to be paying off.

In 2023’s third quarter, the Israeli-American generics giant reported global sales of $3.9 billion, up 7% from the same period in 2022. The company credited that growth to the momentum behind its branded meds Austedo and Ajovy, plus a “stable and sustainable generics business” in the U.S. that’s also seen “continued growth” in Europe and other international markets.